Prostate
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: A GRADE-Assessed Systematic Review and Meta-Analysis.
Nadeem A, et al
A systematic review and meta-analysis of 13 studies encompassing 650 patients found that MRI-guided transurethral ultrasound ablation (TULSA) for localized prostate cancer achieved 100% technical success with major complications (grade ≥ 3) in only 2% of cases. Urinary continence was preserved in 97…
Source →PSMA-PET Tumor Volume Stratifies Nonmetastatic Castration-resistant Prostate Cancer.
Civan C, et al
A large international study of 514 men with nonmetastatic castration-resistant prostate cancer (nmCRPC) found that PSMA-PET imaging detected metastatic disease in 66% of patients previously classified as nonmetastatic by conventional imaging, revealing that tumor volume and the presence of distant m…
Source →Dosimetric and robustness comparison of single- and double-arc volumetric-modulated arc therapy incorporating avoidance structures for prostate cancer with simulated bilateral hip prostheses.
Kato T, et al
Double-arc (DA) volumetric-modulated arc therapy (VMAT) demonstrated marginally superior dosimetric performance and plan robustness compared to single-arc (SA) VMAT for prostate cancer patients with bilateral hip prostheses, though absolute clinical differences were small. In a retrospective analysi…
Source →Current landscape and emerging trends of PD-1/PD-L1 research in prostate cancer: A data-driven atlas from multidatabase integration.
Zhou B, et al
A comprehensive bibliometric analysis of 2,641 publications on PD-1/PD-L1 checkpoint blockade in prostate cancer found that, despite rapid growth in research activity peaking in 2022, current evidence shows limited therapeutic activity in unselected patient populations, with potential benefit concen…
Source →Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform.
Gray S, et al
Contrary to prior concerns that androgen receptor pathway inhibitors increase fracture risk, abiraterone-based treatment intensification significantly reduced fracture-related hospitalisation (FRH) in men with metastatic (M1) prostate cancer: the 5-year FRH incidence was 22% versus 30% for standard …
Source →Predictive Biomarkers in Cancer Immunotherapy for Genitourinary Malignancies.
Paulet A, et al
A new review published in Critical Reviews in Oncology/Hematology synthesizes current and emerging predictive biomarkers for immune checkpoint inhibitor therapy across genitourinary cancers, with urothelial carcinoma — including bladder cancer — as a central focus. The authors evaluate established m…
Source →Lifestyle, anthropometric factors and clinically significant prostate cancer diagnosis in men with suspected prostate cancer.
Heiskanen E, et al
A prospective cohort study of 298 men undergoing prostate cancer diagnostics found that higher physical activity — measured by step count (OR: 0.91, 95% CI: 0.82–0.99) — was inversely associated with detection of clinically significant prostate cancer (csPCa; ISUP grade >1), which was diagnosed in 1…
Source →Development and validation of an integrated intratumoral-peritumoral habitat radiomics model on multiparametric MRI for predicting biochemical recurrence in patients after radical prostatectomy
Ji YT, et al
A new MRI-based combined clinical habitat model (CHPM) integrating intra- and peritumoral radiomics features significantly outperformed the established CAPRA-S scoring system for predicting short-term biochemical recurrence after radical prostatectomy for prostate cancer. Developed and validated in …
Source →Artificial Intelligence in equivocal prostatic needle biopsies: benign mimics and cancer detection.
Bawahab AA
A structured narrative review synthesizing evidence from PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar through May 15, 2026 concludes that AI applied to digitized hematoxylin-and-eosin slides can support cancer detection, grading, workflow prioritization, and quality assurance in diagno…
Source →Salvage treatment strategies for recurrence after radical prostatectomy: Current status, challenges, and future directions.
Ye W, et al
A structured narrative review covering PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library through 20 August 2026 concludes that salvage treatment for prostate cancer recurrence after radical prostatectomy has fundamentally shifted from a one-size-fits-all approach to a precision-based,…
Source →Transdermal Estradiol for Treating Prostate Cancer: Revisiting Huggins and Hodges' Revolutionary Breakthrough.
Benjamin DJ, et al
A review published in European Urology Oncology makes the case for renewed clinical interest in transdermal estradiol — delivered via a skin patch — as a form of androgen deprivation therapy for prostate cancer, the longstanding cornerstone of systemic treatment for this disease. Drawing on evidence…
Source →From risk enrichment to clinical utility: next steps for peri-aortic cardiovascular age.
Lebowitz M, et al
A new perspective published in the European Heart Journal outlines the critical next steps needed to translate peri-aortic cardiovascular age — a novel imaging-derived biomarker of vascular aging — from a risk-enrichment tool into a clinically actionable measure. The authors argue that while peri-ao…
Source →Sodium Channel Blockers Demonstrate Binding Affinity for the Tandem Tudor Domain of the Epigenetic Hub UHRF1.
Tsakalidis E, et al
Researchers have identified hydroxyprocaine, a common local anesthetic, as a potent binder of the tandem Tudor domain (TTD) of the epigenetic regulator UHRF1, achieving a binding affinity of 1.46 μM and establishing it as a viable chemical scaffold for new cancer drug development. Using a combinatio…
Source →Real-World Longitudinal Treatment Outcomes for Patients with Metastatic Castration-Sensitive Prostate Cancer in Japan.
Kawai T, et al
In a large real-world study of 11,737 Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC), androgen receptor signaling inhibitor (ARSI)-based treatments combined with androgen-deprivation therapy (ADT) achieved markedly higher PSA response rates at 3 months than ADT alone …
Source →Disparities and burden of illness among hospitalized cancer patients with opioid dependence.
Faruqui MM, et al
A national inpatient database study of 351,780 hospitalized cancer patients across three cohorts — renal cell carcinoma (RCC; n=88,105), prostate cancer (PC; n=209,410), and cancers of the lip, oral cavity, and pharynx (CLOP; n=54,265) — found that opioid dependence (OD) was consistently associated …
Source →